Released : July 17, 2019 07:00 RNS Number : 7557F MaxCyte, Inc. 17 July 2019 MaxCyte, Inc. ("MaxCyte" or the "Company") Trading Update Significant CARMA™ programme progress, 80+ partnered programmes licensed and strong financial performance with 21% year over year revenue growth
Released : July 11, 2019 07:00 RNS Number : 1593F MaxCyte, Inc. 11 July 2019 MaxCyte, Inc. ("MaxCyte" or the "Company") MaxCyte to Host Capital Markets Day Today Gaithersburg, Maryland - 11 July 2019: MaxCyte (LSE: MXCT, MXCS), the global cell-based therapies and life sciences
Released : July 05, 2019 16:42 RNS Number : 7002E MaxCyte, Inc. 05 July 2019 Second Price Monitoring Extension A second and final Price Monitoring Extension has been activated in this security. The auction call period is extended in this security for a further 5 minutes.
Released : July 05, 2019 16:36 RNS Number : 6992E MaxCyte, Inc. 05 July 2019 Price Monitoring Extension The auction call period has been extended in this security by 5 minutes. Auction call extensions give London Stock Exchange electronic order book users a further opportunity to review the
Released : June 19, 2019 07:00 RNS Number : 7254C MaxCyte, Inc. 19 June 2019 MaxCyte, Inc. ("MaxCyte" or the "Company") 2018 Annual Report Gaithersburg, Maryland - 19 June 2019: MaxCyte (LSE: MXCT, MXCS), the global cell-based medicines and life sciences company, announces that
Released : June 12, 2019 07:00 RNS Number : 8822B MaxCyte, Inc. 12 June 2019 MaxCyte, Inc. ("MaxCyte" or the "Company") Appointment of Joint Corporate Broker Gaithersburg, Maryland - 12 JUNE 2019: MaxCyte (LSE: MXCT, MXCS), the global clinical-stage, cell-based therapies and life
Released : May 29, 2019 07:00 RNS Number : 3926A MaxCyte, Inc. 29 May 2019 MaxCyte, Inc. ("MaxCyte" or the "Company") Save the Date: Capital Markets Day Gaithersburg, Maryland - 29 MAY 2019: MaxCyte (LSE: MXCT, MXCS), the global cell-based medicines and life sciences company,
Released : May 08, 2019 16:41 RNS Number : 4229Y MaxCyte, Inc. 08 May 2019 Second Price Monitoring Extension A second and final Price Monitoring Extension has been activated in this security. The auction call period is extended in this security for a further 5 minutes.
Released : May 08, 2019 16:36 RNS Number : 4224Y MaxCyte, Inc. 08 May 2019 Price Monitoring Extension The auction call period has been extended in this security by 5 minutes. Auction call extensions give London Stock Exchange electronic order book users a further opportunity to review the
Released : May 08, 2019 07:00 RNS Number : 2936Y MaxCyte, Inc. 08 May 2019 MaxCyte, Inc. ("MaxCyte" or the "Company") MaxCyte Progresses Phase I Clinical Trial of Lead mRNA-based Cell Therapy from its CARMA™ Platform - No dose-limiting toxicities or safety concerns observed in
